Introduction
Stroke prevention is central to the management of patients with atrial fibrillation (AF), and effective stroke prevention requires use of oral anticoagulants (OAC) (1) . The latter confers an excess risk of bleeding, and various clinical factors have been associated with bleeding risk (2) .
These clinical factors have been used to formulate bleeding risk scores, to assess the risk of bleeding in atrial fibrillation patients (2) .
Most bleeding risk scores have been derived and/or validated in patients taking Vitamin K antagonists (VKA, eg. warfarin) as the OAC (2) . More recently, the non-VKA oral anticoagulants (NOAC) have been increasingly used for stroke prevention, but limited data are available on the comparative predictive and clinical value of various bleeding risk scores, specifically in NOAC users.
Of the various bleeding risk scores, the HAS-BLED(3) score has been used in various guidelines (4) , but more recently the ATRIA (5) and ORBIT (6) scores have been proposed as alternative scores that appear applicable to the NOAC era. All scores assign integer valued points to a range of risk factors and use the total points to classify into risk strata (low, intermediate, high risk).
Our objective was to compare the predictive value of the stratification schemes proposed by HAS-BLED, ATRIA, and ORBIT bleeding scores in patients with atrial fibrillation treated with NOACs in a nationwide cohort study, using the Danish registries. 
Methods
This study included data from three Danish nationwide databases, which may be linked according to Danish legislation for research purposes. Linkage is enabled by the unique identification number that all Danish citizens hold and is being used throughout all nationwide databases. We used: (i) the Danish National Prescription Registry (7) which holds detailed information on every prescription withdrawal since 1994; (ii) the Danish National Patient Register (8) To establish an OAC naïve cohort, we excluded patients with prior experience of any OAC inclusive doses approved for other indications within one year. Eventually, we excluded patients with prior hospital diagnoses indicating valvular atrial fibrillation (mitral stenosis or mechanical heart valves) or venous thromboembolism (pulmonary embolism or deep venous thromboembolism). This population formed the study cohort for the analyses.
Endpoints and baseline variable definitions
Clinical endpoints were extracted from hospital discharge codes in the Danish National Patient Register using the 10th Revision of ICD codes (see Supplementary Table 1 for specific codes) with follow-up until April 30, 2016. The scores were evaluated on the following bleeding events: intracranial, gastro-intestinal, traumatic intracranial and clinically relevant non-major bleeding reported in total as 'any bleeding' (see supplementary Table 1 for ICD-10 discharge codes).
Primary and secondary inpatient hospital discharge codes were used for endpoint evaluation; to ensure higher validity of the measured outcomes non-emergency ward and outpatient codes were not assessed. Table 1 ) were ascertained from the Danish National Patient Registry and the Danish National Prescription Registry (for code definitions, see Supplementary Table 1 ). Baseline medication was ascertained by the presence of at least one prescription within 365 days prior to study entry, where as comorbidity based on hospital discharge codes included information from hospitalizations and ambulatory visits, but excluding diagnoses coded in emergency wards.
Patient's comorbidities and co-medications at treatment initiation (as listed in
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Based on patient baseline comorbidity and medication, bleeding risk was ascertained using the risk classifications defined by the HAS-BLED(3) , ATRIA (5) , and ORBIT(6) bleeding risk scores (see score definitions in Supplementary Table 2 ). Due to non-availability of data in the national registers, labile INR in the HAS-BLED could not be evaluated, but this criterion was not relevant as all patients were OAC naïve at inclusion and initiated a NOAC treatment.
Renal dysfunction was not uniformly defined in the three scores: in HAS-BLED it is defined as presence of chronic dialysis, renal transplantation, or serum creatinine ≥ 200 m mol/L; in ATRIA: glomerular filtration rate <30 ml/min or dialysis dependent; in ORBIT as insufficient kidney function (eGFR < 60 mg/dL/1.73 m 2 ). We ascertained renal dysfunction as the presence of prior hospital discharge codes indicating insufficient renal function (see Supplementary Table 1; hypertensive kidney disease, acute or chronic glomerulonephritis, hematuria, nephrosis, nephropaty, nephritis, acute or chronic renal insufficiency, polycystic kidney disease). Thus, we applied a generic definition and did not distinguish between bleeding score definitions of renal dysfunction in our study.
The ATRIA and ORBIT scores assigned points for anemia, and the ORBIT score further included information regarding abnormal haemoglobin (<13 mg/dL for males and <12 mg/dL for females) or haematocrit (<40% for males and <36% for females). In the present evaluation, we only included hospital discharge information regarding anemia due to non-availability of laboratory data.
The HAS-BLED score assigns risk scores in the range 0 to 8 and the following risk strata categorization was suggested(3): low risk as scores 0-2 and high risk for scores ≥3. The ATRIA score assigns risk in the range 0 to 10 with the risk strata classification (10) In the present study all scores risk classification were considered as dichotomized to low risk vs intermediate/high risk.
Statistical analysis
Detailed statistical methods are provided in the Supplementary Materials. In brief, risk strata were compared using Cox-proportional hazards regression. Discrimination based on the dichotomized risk classification was evaluated using C-statistics based on time-dependent areas under the ROCcurves, both acknowledging survival data and competing risk for death (11) . The net benefit (NB) for assigning intermediate/high risk was evaluated by decision curve analysis (12) (13) . The risk threshold is the anticipated treatment risk at which the utility of treatment equals the cost of avoiding treatment.
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Results A total number of 57,930 OAC naïve non-valvular atrial fibrillation patients were identified and included in this study [Supplemental figure 1]. Females accounted for 44.6% and the mean age (SD) was 73.5 (11.4) years. The mean CHA 2 DS 2 -VASc score for stroke risk was 3.2 (1.8), with hypertension being the most prevalent risk factor (59.0%). Further population baseline characteristics are summarised in Table 1 .
The distributions of the individual bleeding score levels are shown in Table 2 , with the mean scores ranging from 1.4 (ORBIT) to 2.4 (HAS-BLED) with ATRIA being intermediate with mean 2.0.
The ATRIA and ORBIT scores categorized 12.7% and 16.4% of the study population, respectively, as being at intermediate/high bleeding risk, whereas this proportion using HAS-BLED was 46.8%.
Event rates in relation to bleeding risk scores
The overall event rate (per 100 person-years) of the combined bleeding endpoint was 2.41 at 1
year of follow-up. The 1-year bleeding rates ranged between 0.47 and approximately 11.3 across individual score levels with the lowest rate identified by HAS-BLED score level 0. The score level 0 groups of ATRIA and ORBIT both had bleeding rates of 0.80-0.90 per 100 person-years ( Table 2) . 
Predictive value of bleeding scores
In terms of discrimination, Table 3 shows C-statistics at 1 year follow-up for ATRIA as 0.59 (95% CI 0.57-0.60), HAS-BLED 0.58 (95% CI 0.57-0.59), and ORBIT 0.61 (95% CI 0.59-0.62), with ORBIT displaying statistically significant difference from both ATRIA and HAS-BLED (p<0.001). At the 2.5 years follow-up, comparable statistics were obtained (Supplementary figure 3) .
Qualitatively, HAS-BLED show higher sensitivity (62.8%) for categorizing intermediate/high risk compared to ATRIA (29.7%) and ORBIT (37.1%) at the expense of reduced specificity for categorization as intermediate/high risk (specificity: HAS-BLED 53.5%; ATRIA 87.6%; ORBIT 84.0%).
In this population, the positive predictive values ranged from 3.0% (HAS-BLED) to 5.2% (ATRIA, ORBIT), and with all negative predictive values above 98.2% at 1 year (Table 3 ). After 2.5 years, the PPVs overall increased by approx. 70% (HAS-BLED: 5.4%, ORBIT: 8.8%, ATRIA: 9.2%) whereas NPV was essentially unchanged ( Supplementary Table 4 ).
Decision curve analysis
The clinical usefulness was evaluated by use of decision curves, as presented in Figure 3 . The potential benefit of being guided by the score classification is linked to the assumed threshold for intervention, which in this study should be considered as the patient being subjected to more extensive monitoring to avoid bleeding incidences. At a 1 year perspective, and if the threshold is low (<1.7%), the benefit is towards monitoring all patients. If preference is to thresholds ranging 1.7% and 2.0%, most benefit was obtained by using the HAS-BLED score as guidance. The ORBIT or ATRIA scores provided better benefit for thresholds between 2% and 6%.
If the preferred threshold for intervention is above 6%, none of the tested scores will have positive benefit, since the intermediate/high risk categories identified as a whole have an incidence of bleeding at maximum of 6% (Figure 3) .
The relations between the scores were maintained at 2.5 years of follow-up although the thresholds were shifted upwards (Supplementary Figure 4 ).
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Discussion
Our principal finding is that at 1 year follow-up, predictive values (using AUC/C-statistics) for ATRIA, HAS-BLED and ORBIT risk score classifications were broadly similar and performances were modest. Second, both ATRIA and ORBIT categorized more patients as 'low risk' and qualitatively, there was higher sensitivity on the expense of specificity and positive predictive value for HAS-BLED compared to ATRIA and ORBIT. Third, decision curve analyses at a 1 year perspective shows that if preference is for a major bleeding risk threshold between 1.7-2.0%, most benefit was obtained by using HAS-BLED, whereas the ORBIT and ATRIA scores provided better benefit for thresholds between 2.6-6.0%. As far as we are aware this is the largest "real world" analysis of bleeding risk scores in atrial fibrillation patients who are NOAC users, based on an entire nationwide cohort (and not selective insurance provider claims data).
The use of bleeding risk scores has been subject to misinterpretation and misuse (14) . Bleeding risk assessment should be part of the holistic management of atrial fibrillation patients being started on antithrombotic therapy. While modifiable bleeding risk factors should be addressed in all anticoagulated patients, a high bleeding risk score per se should be a help to treating physicians by 'flagging up' those patients at risk of bleeding for more regular review and follow-up (which is relevant these days in the era of Electronic Health Records (EHR) (14) ).
Since many bleeding risk factors are potentially modifiable, for example, (uncontrolled) hypertension, concomitant use of aspirin or NSAIDs, alcohol excess, etc -a useful bleeding risk score should draw attention to these reversible factors, so they can be addressed (2) . In a VKA user, labile INR (as reflected by poor time in therapeutic range, TTR) is a powerful determinant of bleeding (and thromboembolism) risk (15) , but this criterion in HAS-BLED is not applicable in NOAC users. Bleeding risk assessment is also a dynamic process, and should be applicable at all stages of the patient management pathway: when first diagnosed on no antithrombotic therapy (or aspirin) and following OAC initiation. A high bleeding risk score is not a reason to withhold OAC, as the net clinical benefit balancing ischaemic stroke reduction against serious bleeding is even greater in such patients (16) .
The HAS-BLED score was initially derived from the EuroHeart survey atrial fibrillation population on VKA, and has been subsequently validated in patient cohorts who are not taking any antithrombotic therapy, aspirin and OAC (whether VKA or non-VKA users), as well as in atrial fibrillation and non-atrial fibrillation cohorts in trial and non-trial (ie. 'real world') patients Page 11 of 36 populations(3) (17) (18) (19) . The ATRIA bleeding score was derived from the ATRIA community cohort amongst VKA users, and validated in the ROCKET-AF trial population, while the ORBIT score was derived from the ORBIT registry, where most were VKA users(5) (6) . In the derivation studies(3) (5) (6), the rates for low risk were in the derivation/validation cohorts at maximum 3.20/1.88 (respectively) for the HAS-BLED score, 2.9 in ORBIT (missing validation cohort), and 0.88/1.27 in ATRIA derivation/validation cohorts. The rates for high-risk groups were at least 19.51/3.74 in HAS-BLED derivation/validation cohorts, 6.8 in ORBIT derivation cohort, and 6.34/4.18 in ATRIA derivation/validation cohorts. Highlighting, that these studies did not apply comparable risk thresholds when assigning risk classification. Withholding these classifications, as in the present study, recent analyses amongst VKA users clearly show that ATRIA and ORBIT would have a significantly poorer predictive value for clinically relevant or major bleeding or ICH compared to HAS-BLED, by not considering the labile INR criterion (20, 21) .
In correspondence with the score comparison based on the AMADEUS trials(21) ATRIA and ORBIT categorized >85% as 'low risk' which may lead to non-alerts from EHR, and patients not 'flagged up' for review and follow-up. The lower risk threshold of HAS-BLED thus on the other hand lead to higher sensitivity on the expense of a lower specificity and positive predictive value. As shown in our decision curve analysis, if the preference is for a major bleeding risk intervention threshold between 1.3-1.8%, most benefit was obtained by using the HAS-BLED score, while ORBIT provided better benefit for thresholds between 1.8-3%; and ATRIA at >3%. In comparison a stroke treatment threshold for OAC has been proposed for approximately 1.0-1.7%/year (22) , which was based on quality-adjusted life-year analysis. A similar bleeding risk threshold approach to aid decision-making could prove useful for treating physicians. Yet, stroke and bleeding risk stratification may not easily translate into individual patient evaluation, and decisions on life-long antithrombotic treatment should cover the patient as a whole, and not be confined to risk estimates from population-based studies. Nevertheless, our decision curve analysis may hint a preferred score on the expense on another in case an appropriate threshold can be agreed upon.
In accordance, the recent European Society of Cardiology (ESC) guidelines do not recommend a specific bleeding risk score, but tabulates a long list of modifiable, non-modifiable and biomarkerrelated bleeding risk factors (23) . As highlighted above, this precludes use of a simple risk score to aid follow-up decisions or to help flag up patients at risk for more regular review and follow-up.
While emphasis on reversible bleeding risk factors are paramount, the suggestion of a biomarkerbased bleeding predictor is less useful given that many biomarkers are predictive of bleeding as Page 12 of 36 13 well as stroke, myocardial infarction, heart failure, sudden death etc., which could lead to confusion amongst clinicians over which endpoint to focus on. In addition, one may question the generalizability of biomarker predictions of bleeding, since these studies were based on highly selected anticoagulated cohorts in the NOAC randomized trials, where bloods tests are baseline were used for predicting events over many years of follow-up (14) (24) (25) (26) . Indeed, in a real world anticoagulated atrial fibrillation cohort, the HAS-BLED score performed better than a biomarker based score in predicting major bleeding (27) . Hence, clinical management of atrial fibrillation patients would be best served with a simple clinical bleeding risk score that is used appropriately.
Study limitations
The main limitations pertain to the observational nature of our study with a potential of low generalizability due to possible bias from selective prescribing. Specifically, we only included users of NOACs, and atrial fibrillation patients deemed inappropriate for this treatment were not investigated (e.g. end-stage renal kidney disease). The scores differ in some details on the definition of specific risk factors, which could not be ascertained due to lack of laboratory data; these may influence the score distribution. Observational cohorts have a risk of misclassification but the outcomes ascertained have been previously validated with a high positive predictive value (e.g. 97-100% for ischemic stroke) (28) . In addition, endpoints were not adjudicated (unlike a trial cohort) and post mortems were not mandated; therefore, some severe bleeding episodes with fatal consequences may not have been fully captured in the coding applied for endpoint analysis.
Patient adherence to the NOACs and prescribing practices were not considered. Our data apply to a predominantly white European population, and differential efficacy and safety benefits may be evident between Asians and non-Asians (29, 30) .
Conclusions
This analysis of contemporary bleeding risk scores in a 'real world' NOAC user population with atrial fibrillation showed modest predictive performance in terms of C-statistics. The scores represent different risk thresholds with HAS-BLED classifying least patients at low risk and achieving the highest benefit if applying a major bleeding intervention threshold of approx. 2.0%, whereas benefit from using either ATRIA score or ORBIT score was evident using higher intervention thresholds. 
HAS-BLED
SUPPLEMENTARY MATERIAL
Detailed statistical methods
Study population
The study was based on new users of NOAC with no hospital information for treatment for other indications than atrial fibrillation.
We identified patients with first-time purchases of each NOAC approved for atrial fibrillation from their respective dates of approval for atrial fibrillation: apixaban (December 10, 2012), dabigatran (August 10, 2011), rivaroxaban (February 1, 2012).
Patient inclusion was terminated by February 28, 2016.
Statistical analyses
For each score, crude event rates were calculated as number of events divided by person years for each score level and for each risk classification strata. The event risk up to 2.5 years follow-up was depicted in terms of cumulative incidence functions based on the Aalen-Johansen estimator acknowledging competing risk for death. Risk strata were compared using Cox-proportional hazards regression.
To visualize the predictive performance for the three scores from their respective derivation cohort and the data applied in current study, the points from each scoring system were plotted against the event rates of bleeding. Discrimination based on the dichotomized risk classification was evaluated using C-statistics based on time-dependent areas under the ROC-curves, both acknowledging survival data and competing risk for death (11) . Also negative and positive predicted values were reported.
Confidence intervals for reported measures were based on 500 bootstrap samples.
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The net benefit (NB) for assigning intermediate/high risk was evaluated by decision curve analysis by weighing the proportion of true positives (TP) against the false positives (FP) as (TP -w * FP)/N, with "w" as penalty for false positive (12) . In decision curve analysis, w is defined as p/ (1-p) , where p is a selected risk threshold for "intervention" (13) . The risk threshold is the anticipated treatment risk at which the utility of treatment equals the cost of avoiding treatment. Under this definition it can be derived that Supplementary Table 1 Definitions on comorbidity and concomitant medication according to ICD-10 codes and ATC-codes. Conditions marked with † was used in the calculation of the CHA2DS2-VASc score. Conditions marked with # was used in the calculation of the HAS-BLED score.
International Classification of Diseases 10th revision (ICD-10) code NSAIDs: Non Steroidal Anti Inflammatory Drugs. * We identified subjects with hypertension from combination treatment with at least two of the following classes of antihypertensive drugs: I· Alpha adrenergic blockers (C02A, C02B, C02C) II· Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52) III· Vasodilators (C02DB, C02DD, C02DG, C04, C05) IV· Beta blockers (C07) V· Calcium channel blockers (C07F, C08, C09BB, C09DB) VI· Renin-angiotensin system inhibitors (C09) As well as combination drugs: C07B, C09BB04, C09DA, C09DB, C09DX01, C09DX04 
